Medical Oncology melanoma research

In 2014, our focus in melanoma research moved from advanced disease to treating earlier stage disease with the hope of finding effective systemic adjuvant treatments.

Earlier research involving many Alfred patients established targeted therapy as the new standard of care for advanced melanoma in which a B-Raf mutation is detected.

In 2014 we were involved in two large international studies looking at the role of targeted therapies as potential adjuvant treatments for stage III melanoma. As the highest recruiter in Victoria to these studies, The Alfred has played a major role in rapidly moving this area forward.

In other translational research, Dr Haydon is a co-investigator on a multimillion VCA award entitled ‘The Melbourne Melanoma Project: Translating immunology and molecular biospecimen profiles into the management of melanoma patients’. This project is led by Professor Grant McArthur of Peter MacCallum Cancer Centre and other Alfred Research Alliance participants are the heads of the Victorian Melanoma Service (Professor John Kelly) and Anatomical Pathology (Professor Catriona McLean).

Melanoma research is also conducted by the Victorian Melanoma Service, in partnership with the Medical Oncology and the Melbourne Melanoma Project.

Find out more about Victorian Melanoma Service research.

Our partners

Publications

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database

Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ

(2023), European Journal of Cancer, 178, 162-70

DOI: 10.1016/j.ejca.2022.10.022

Design, optimisation and standardisation of a high-dimensional spectral flow cytometry workflow assessing T-cell immunophenotype in patients with melanoma

Edwards JM, Andrews MC, Burridge H, Smith R, Owens C, Edinger M, Pilkington K, Desfrancois J, Shackleton M, Senthi S, van Zelm MC

(2023), Clinical & Translational Immunology, 12(9), e1466

DOI: 10.1002/cti2.1466

Immune-related adverse events secondary to immunotherapy in oncology

Yeoh, Hui-Ling; Freilich, Karen Belinda; Voskoboynik, Mark; Moore, Maggie; Andrews, Miles Cameron Gregory; Shackleton, Mark; Haydon, Andrew Mark Meurisse

(2023), Australian Journal of General Practice, 52(6), 378-385

DOI: 10.31128/AJGP-04-22-6408

View all publications for Medical Oncology melanoma research